Trial Profile
4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of PUR 0110 (Thykamine™) Cream Applied Twice Daily in Mild-to-Moderate Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Thykamine (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors PurGenesis Technologies
- 16 May 2023 According to a Devonian media release, results of this study will be presented at the upcoming 25th World Congress of Dermatology to be held in Singapore from July 3rd to 8th.
- 12 Oct 2022 According to a Devonian media release, results from this trial will be presented at the upcoming 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases ("ADDDS") 2022.
- 06 Oct 2022 According to a Devonian media release, results from the trial are published in the Journal of Drugs in Dermatology (JDD).